Physician profile
Stephanie Murphy
NPI 1811245434
$9,075.31
in general payments reported to CMS, 2019-2025
38 companies · $2,008 in 2025
The $2,008 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,448 · 2022: $1,552 · 2023: $2,224 · 2024: $1,843 · 2025: $2,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,054 · Education: $20.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,054.00 |
| Education | $20.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,271.81 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,069.70 | 2021-2025 | Xifaxan, Trulance, Uceris |
| Janssen Biotech, INC. | $1,001.76 | 2021-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $752.86 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $431.60 | 2022-2025 | |
| Gilead Sciences, INC. | $415.76 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $270.32 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $270.21 | 2021-2024 | Dificid |
| Janssen Scientific Affairs, LLC | $255.33 | 2022-2023 | Stelara |
| E.R. Squibb & Sons, L.L.C. | $215.71 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $211.13 | 2021-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $173.74 | 2022-2025 | Dupixent |
| Redhill Biopharma INC. | $160.12 | 2021-2023 | Aemcolo, Movantik, Talicia |
| Ferring Pharmaceuticals INC. | $154.58 | 2023-2025 | Rebyota, Clenpiq |
| Ironwood Pharmaceuticals, INC | $151.51 | 2021-2024 | Linzess |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $150.98 | 2023-2025 | Ibsrela |
| Celgene Corporation | $128.09 | 2022-2024 | Zeposia |
| Pfizer INC. | $120.83 | 2023-2025 | |
| Organon LLC | $117.53 | 2023-2025 | Renflexis, Hadlima |
| Madrigal Pharmaceuticals | $105.02 | 2024-2025 | Rezdiffra, Resmetirom |
| Sandoz INC. | $99.26 | 2024-2025 | Hyrimoz |
| Amgen INC. | $95.41 | 2021-2023 | Amjevita, Avsola |
| Qol Medical, LLC | $64.57 | 2021-2024 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $50.98 | 2023-2025 | Suflave |
| Evoke Pharma, INC. | $45.67 | 2021-2023 | Gimoti |
| Exact Sciences Corporation | $44.97 | 2023-2024 | Cologuard Collection Kit |
| Csl Behring | $35.97 | 2021 | |
| Lilly USA, LLC | $35.44 | 2024-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $22.49 | 2023 | |
| Ucb, INC. | $21.18 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.96 | 2025 | |
| Alnylam Pharmaceuticals INC. | $18.77 | 2025 | Givlaari |
| Fresenius Kabi USA, LLC | $16.38 | 2023 | Idacio |
| Novo Nordisk INC | $15.78 | 2021 | |
| Daiichi Sankyo INC. | $15.76 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.64 | 2023 | Cyltezo |
| Pharmacosmos Therapeutics INC. | $14.69 | 2021 | |
| Alfasigma USA, INC. | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.